Sanofi Consumer Healthcare India Limited (SCHIL) held its first Institutional Investor Meet on 24th March 2026, filed under Regulation 30 of SEBI LODR.
Company reported ₹880 crore turnover, ~37% Profit from Operations margin, 62.5% ROCE, with FY2025 PAT up 33% and Revenue from Operations up 21%.
Management outlined three growth levers: doubling HCP reach (target 2026), scaling consumer/digital engagement, and 2X increase in direct retail store coverage.
All recalled products are back in market, with 2 of 4 brands back to pre-recall run rates; e-commerce and modern trade contribution currently in single digits.